

Eduarda Silva<sup>1</sup>, Rita Pena<sup>1</sup>, Armandina Miranda<sup>2</sup>, Alcina Costa<sup>2</sup>, Gisela Gaspar<sup>2</sup>, Pedro Lopes<sup>1</sup>, Paula Faustino<sup>1,3,4</sup>


1. Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa.
2. Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa.
3. Grupo Ecogenética e Saúde Humana, Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa, Lisboa.
4. Laboratório Associado TERRA, Faculdade de Medicina, Universidade de Lisboa, Lisboa.

## Introduction

**Hemoglobinopathies** encompass all genetic diseases of hemoglobin (Hb), the iron-containing oxygen-transport protein present in red blood cells<sup>1,2</sup>. They have autosomal recessive transmission and are due to molecular changes in globin genes or in their regulatory regions<sup>3</sup>. Hemoglobinopathies include **Hb variants** (mainly caused by missense mutations) and **Thalassemias** (due to nonsense and frameshift mutations or indels)<sup>4,5</sup>. Globin genes are located in two globin gene clusters and have differential temporal expression (Figure 1).

## Aims

We aimed to identify the molecular lesions in the origin of complex cases of hemoglobinopathies and understand the underlying pathophysiological mechanisms.




**Figure 1.** Schematic representation of the human  $\alpha$ - and  $\beta$ -globin gene clusters and their distal regulatory elements. (a) The  $\alpha$ -globin gene cluster on chromosome 16 p13.3 includes the  $\zeta$ ,  $\alpha 2$  and  $\alpha 1$  genes. The vertical arrow indicates the location of the major regulatory upstream hypersensitive site (HS-40), crucial for the *in cis* gene expression. The  $\alpha 2$ -globin gene structure is shown below with the three coding exons (striped boxes), the two introns (open boxes), and the untranslated regions (zigzag boxes). (b) The  $\beta$ -globin gene cluster on chromosome 11 p15.4 includes the  $\epsilon$ ,  $\gamma$ ,  $\delta$  and  $\beta$  genes, arranged in the order of their developmental expression. Upstream of these genes is the Locus Control Region ( $\beta$ -LCR) constituted by five hypersensitive sites indicated by vertical arrows. As in panel a), the  $\beta$ -globin gene is expanded to show its structure<sup>6</sup>.

## Materials and Methods

- ✓ We investigated **15 clinical cases** suspected of having one or more hemoglobinopathy, presenting with atypical hematological phenotypes.
- ✓ The study included the search for alterations in  $\beta$ - and  $\alpha$ -globin gene clusters by PCR, ARMS, Gap-PCR, Multiplex Gap-PCR, Sanger sequencing, and Multiplex Ligation-dependent Probe Amplification (MLPA).
- ✓ *In silico* analyses were performed using Polyphen-2, SIFT, and varSeak.


## Results and Discussion

### ABNORMALLY LOW HbA<sub>2</sub> LEVEL IN $\beta$ -THALASSEMIA CARRIERS




**Figure 2.** Partial Sanger sequencing electropherograms revealing (a) the alteration *HBD:c.82G>T* in heterozygosity responsible for the Hb variant **HbA<sub>2</sub>-Yialousa**<sup>7</sup> and (b) the alteration *HBD:c.49G>C*, also in heterozygosity, responsible for the **HbA<sub>2</sub>'** variant<sup>7</sup>.

### 7.2kb Corfu Deletion – Involving the $\delta$ -globin gene




**Figure 3.** a) MLPA results revealing the presence of a deletion in heterozygosity affecting the  $\delta$ -globin gene, whose size is suggestive of being the -7.2 kb Corfu deletion<sup>7</sup>. b) Electrophoretic profile of the products obtained by the Gap-PCR performed for the confirmation of the diagnosis of the Corfu deletion: M – molecular weight marker; 1 – Normal control sample; 2 – Propositus DNA fragments revealing heterozygosity for the deletion; 3 – Homozygous -7.2 kb Corfu deletion control; 4 – negative control.

### ABNORMALLY HIGH FETAL HEMOGLOBIN LEVEL IN $\beta$ -THALASSEMIA CARRIERS




**Figure 4.** Partial Sanger sequencing electropherograms revealing two alterations in the  $\gamma$ -globin gene promoter, which explain the non-deletional Hereditary Persistence of Fetal Hemoglobin (HPFH)<sup>7</sup> in two cases: (a) *HBG1:c.-248C>G*, responsible for the HPFH Brazilian<sup>7</sup>; (b) *HBG1:c.-228T>C*, responsible for the HPFH Black<sup>7</sup>.

### HPFH-1 and HPFH-2 Deletions – Removing the $\delta$ and $\beta$ -globin genes




**Figure 5.** MLPA results revealing two different large deletions, both in heterozygosity, which remove the  $\delta$ - and the  $\beta$ -globin genes and give rise to high expression of  $\gamma$ -globin genes and very high levels of fetal hemoglobin (HbF): (a) a deletion similar to the reported **HPFH-1** (84918 bp)<sup>7</sup> found in an individual with HbF=17.5%; (b) a deletion similar to the reported **HPFH-2** (84281 bp)<sup>7</sup> found in a sickle cell anemia carrier with HbF=24.3%.

### A VERY COMPLEX CASE OF TRIPLE HETEROZYGOSITY FOR TWO HEMOGLOBIN VARIANTS AND $\alpha$ -THALASSEMIA




**Figure 6.** Partial Sanger sequencing electropherograms revealing (a) the alteration *HBA2:c.369C>G* in hemizyosity responsible for the **Hb Westmead**<sup>7</sup>, an  $\alpha$ -chain Hb variant; (b) the alteration *HBB:c.79G>A*, in heterozygosity, responsible for the **HbE**<sup>7</sup>, a  $\beta$ -chain Hb variant.

### Southeast Asian Deletion – Removing the $\alpha 2$ - and $\alpha 1$ -globin genes



**Figure 7.** MLPA results showing of a large deletion in heterozygosity, which completely removes the *HBAP1*, *HBA2*, *HBA1*, and *HBA3* genes in the  $\alpha$ -globin gene cluster, giving rise to  $\alpha^0$ -thalassemia. It was identified by Multiplex Gap-PCR as Southeast Asian deletion<sup>7</sup> with 20.5 kb in length.

### A DELETION THAT REMOVES THE ENTIRE $\beta$ -GLOBIN GENE CLUSTER



**Figure 8.** MLPA results showing a probably novel large deletion in heterozygosity, which removes the entire  $\beta$ -globin gene cluster, including the LCR, as well as the olfactory receptor genes, *OR52A1* and *OR51V1*. This deletion may have 196.6 to 730.3 kb in length.

## Conclusions

- Individuals presenting abnormal phenotypes due to more than one hemoglobinopathy may be misdiagnosed if not correctly studied.
- Unravelling the genetic basis of complex clinical cases allows a better referral to genetic counselling, improves the understanding of the pathophysiology of the disease and its modifying factors, and may reveal new therapeutic targets.

## References

1. Hoffman R, Benz E, J., Heslop H, Weitz J & Elsevier. *J. Hematology: Basic Principles and Practice*. (2018).
2. Trent R. J. A. *Diagnosis of the haemoglobinopathies*. *Clin. Biochem. Rev.* 27, 27–38 (2006).
3. Sarnaik S. A. *Thalassemia and related hemoglobinopathies*. *Indian J. Pediatr.* 72, 319–324 (2005).
4. Nussbaum RL, McInnes RR, Willard HF, Thompson JS, Thompson MW. *Genetics in medicine*. 8<sup>th</sup> ed. Elsevier, editor. Saunders Philadelphia, 512-540 (2015).
5. Trent R. J. A. *Diagnosis of the haemoglobinopathies*. *Clin. Biochem. Rev.* 27, 27–38 (2006).
6. Samarrah F, Athanasiou-Metaxa M, & Vavatsi-Christaki N. Genetic modulators of sickle cell disease. *Aristotle Univ. Med. J.* 34, 25–35 (2007).
7. *Globin Gene Server database*.